IM Cannabis Corp 6-K, filed Jul 27, 2026
IM Cannabis Corp. (IMCC)
6-K
2026-07-27
For: 2026-07-27
View Original
Added on
July 27, 2026
About this 6-K
IM Cannabis Corp filed this 6-K on July 27, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026 (Report No. 2).
Commission File Number: 001-40065
IM Cannabis Corp.
(Exact Name of Registrant as Specified in Charter)
Kibbutz Glil Yam, Central District, Israel 4690500
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Resignation of a Director
On July 26, 2026, Mr. Alon Dayan notified the board of directors of IM Cannabis Corp. (the “Company”) of his resignation from his position as a member of the board of directors, effective July 26,
2026. Mr. Dayan’s resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
Press Release
On July 27, 2026, the Company issued a press release titled: “IM Cannabis Provides Corporate Update”. A copy of this press release is furnished herewith as Exhibit 99.1.
Incorporation by Reference
This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-296637, 333-293236, 333-289571 and 333-288346) filed with the U.S. Securities and
Exchange Commission to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
|
Exhibit No.
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
|
IM CANNABIS CORP.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date: July 27, 2026
|
By:
|
/s/ Oren Shuster
|
|
|
Name:
|
Oren Shuster
|
|
|
Title:
|
Chief Executive Officer and Director
|
Exhibit 99.1
IM Cannabis Provides Corporate Update
TORONTO and GLIL YAM, Israel, July 27, 2026 – IM Cannabis Corp. (“IMC” or
the “Company”) (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, announces that Mr. Alon Dayan has resigned as a
director of the Company for personal reasons.
The board of directors and management of IM Cannabis thank Mr. Dayan for his service and valuable contributions to the Company during
his tenure and extend their best wishes to him in his future endeavours.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global
markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.
The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging
years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In
Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Company Contact:
Michal Efraty
Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com
IM Cannabis Corp.
michal@efraty.com
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
info@imcannabis.com
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian
securities laws and, where applicable, United States securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s evaluation of opportunities to expand into additional
technology-driven sectors and the Company’s business focus, strategy and future opportunities.
Forward-looking statements are based on the beliefs, expectations and assumptions of management as of the date of this press release,
including assumptions regarding the Company’s ability to continue operating its medical cannabis platform in Israel and Germany, the availability of opportunities that are consistent with the Company’s business strategy, the Company’s ability to
evaluate and pursue such opportunities, market conditions, regulatory conditions and the continued availability of required licences, permits and approvals.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results,
performance or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, risks relating to the highly regulated nature of the medical cannabis
industry, the Company’s ability to maintain applicable licences, permits and regulatory approvals, changes in applicable laws, regulations and enforcement practices, market and business conditions in Israel and Germany, the availability and
suitability of strategic opportunities, the Company’s liquidity and capital resources, and the risks described under the heading “Risk Factors” in the Company’s most recent annual report and other continuous disclosure documents filed on SEDAR+ at
www.sedarplus.ca and on EDGAR at www.sec.gov.
Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this
press release are made as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking statements, except as required by applicable securities laws.